Northern Trust
ATNM icon

Northern Trust’s Actinium Pharmaceuticals ATNM Stock Holding History

Northern Trust’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.5K Buy
75,855
+33,245
+78% +$39.5K ﹤0.01% 4165
2025
Q4 		$58K Buy
42,610
+6,715
+19% +$9.8K ﹤0.01% 4254
2025
Q3 		$57.4K Sell
35,895
-24,096
-40% -$39.3K ﹤0.01% 4261
2025
Q2 		$84K Sell
59,991
-168,281
-74% -$252K ﹤0.01% 4147
2025
Q1 		$368K Sell
228,272
-23,658
-9% -$30K ﹤0.01% 3700
2024
Q4 		$317K Buy
251,930
+11,812
+5% +$18.3K ﹤0.01% 3827
2024
Q3 		$451K Buy
240,118
+11,659
+5% +$46.1K ﹤0.01% 3607
2024
Q2 		$1.69M Sell
228,459
-2,146
-0.9% -$17.7K ﹤0.01% 2990
2024
Q1 		$1.81M Buy
230,605
+4,213
+2% +$27.1K ﹤0.01% 3013
2023
Q4 		$1.15M Buy
226,392
+6,008
+3% +$30.9K ﹤0.01% 3263
2023
Q3 		$1.3M Buy
220,384
+1,048
+0.5% +$6.97K ﹤0.01% 3176
2023
Q2 		$1.63M Buy
219,336
+174,776
+392% +$1.49M ﹤0.01% 3127
2023
Q1 		$421K Sell
44,560
-224
-0.5% -$2.36K ﹤0.01% 3535
2022
Q4 		$477K Buy
44,784
+5,551
+14% +$56.3K ﹤0.01% 3521
2022
Q3 		$289K Buy
39,233
+1,179
+3% +$7.33K ﹤0.01% 3694
2022
Q2 		$183K Buy
38,054
+684
+2% +$3.88K ﹤0.01% 3972
2022
Q1 		$191K Sell
37,370
-616
-2% -$3.24K ﹤0.01% 4146
2021
Q4 		$229K Sell
37,986
-343
-0.9% -$2.57K ﹤0.01% 4150
2021
Q3 		$339K Buy
38,329
+277
+0.7% +$1.93K ﹤0.01% 3923
2021
Q2 		$301K Buy
38,052
+10,950
+40% +$85.9K ﹤0.01% 3932
2021
Q1 		$207K Sell
27,102
-218
-0.8% -$1.85K ﹤0.01% 4107
2020
Q4 		$213K Buy
27,320
+376
+1% +$4.08K ﹤0.01% 3945
2020
Q3 		$261K Sell
26,944
-1,283
-5% -$14.1K ﹤0.01% 3756
2020
Q2 		$298K Buy
28,227
+17,659
+167% +$134K ﹤0.01% 3664
2020
Q1 		$62K Buy
10,568
+1,432
+16% +$10.2K ﹤0.01% 3915
2019
Q4 		$60K Hold
9,136
– – ﹤0.01% 4024
2019
Q3 		$63K Hold
9,136
– – ﹤0.01% 4017
2019
Q2 		$67K Hold
9,136
– – ﹤0.01% 4034
2019
Q1 		$132K Hold
9,136
– – ﹤0.01% 3862
2018
Q4 		$106K Hold
9,136
– – ﹤0.01% 3905
2018
Q3 		$203K Buy
9,136
+5,590
+158% +$114K ﹤0.01% 3862
2018
Q2 		$68K Hold
3,546
– – ﹤0.01% 4075
2018
Q1 		$39K Hold
3,546
– – ﹤0.01% 4110
2017
Q4 		$71K Hold
3,546
– – ﹤0.01% 4031
2017
Q3 		$61K Hold
3,546
– – ﹤0.01% 4035
2017
Q2 		$130K Hold
3,546
– – ﹤0.01% 3910
2017
Q1 		$161K Buy
3,546
+1,453
+69% +$55.8K ﹤0.01% 3848
2016
Q4 		$55K Buy
2,093
+96
+5% +$3K ﹤0.01% 3999
2016
Q3 		$81K Buy
1,997
+34
+2% +$1.75K ﹤0.01% 3937
2016
Q2 		$104K Buy
1,963
+443
+29% +$24.7K ﹤0.01% 3883
2016
Q1 		$91K Hold
1,520
– – ﹤0.01% 3925
2015
Q4 		$147K Hold
1,520
– – ﹤0.01% 3847
2015
Q3 		$81K Sell
1,520
-6,392
-81% -$427K ﹤0.01% 3980
2015
Q2 		$629K Buy
7,912
+426
+6% +$36.4K ﹤0.01% 3501
2015
Q1 		$555K Buy
7,486
+567
+8% +$67.4K ﹤0.01% 3578
2014
Q4 		$1.22M Buy
6,919
+180
+3% +$34.2K ﹤0.01% 3328
2014
Q3 		$1.35M Buy
6,739
+5,488
+439% +$1.09M ﹤0.01% 3314
2014
Q2 		$271K Buy
+1,251
New +$417K ﹤0.01% 3763

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust's ATNM Position: Q1 2026 in Review

Northern Trust increased its Actinium Pharmaceuticals (ATNM) stake by 78% in Q1 2026, buying an estimated $39.5K and bringing the position to 75,855 shares worth $75.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

Northern Trust first reported a position in ATNM in Q2 2014 and has held it in 48 quarters since. The position peaked at $1.81M in Q1 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Northern Trust held 75,855 shares of Actinium Pharmaceuticals worth $75.5K as of Q1 2026.
  • Northern Trust bought 33,245 Actinium Pharmaceuticals shares in Q1 2026, an estimated $39.5K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4165 holding.
  • Northern Trust first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
  • Northern Trust's Actinium Pharmaceuticals position peaked at $1.81M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.